UB Paderborn / Katalog / Suche / in CDI

P07 BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD) IN REAL‐LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL

HemaSphere, 2023-05, Vol.7 (S2), p.12-13

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of nivolumab monotherapy in cirrhotic patients with advanced hepatocellular carcinoma: a single-center retrospective study

Digestive and liver disease, 2023-09, Vol.55, p.S212-S213

2023

Link zum Volltext

Verfügbarkeit prüfen

Single centre experience with Nivolumab as monotherapy in chirrotic patients with advanced HCC

Digestive and liver disease, 2023-03, Vol.55, p.S61-S61

2023

Link zum Volltext

Verfügbarkeit prüfen

Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: a report of two international experiences

Digestive and liver disease, 2024-02, Vol.56, p.S88

2024

Link zum Volltext

Verfügbarkeit prüfen

5PSQ-175 Cytotoxic T lymphocyte antigen 4 mutations on T reg and abatacept: a paediatric case report

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A142-A142

2021

Link zum Volltext

Verfügbarkeit prüfen

5PSQ-158 Off-label use of pembrolizumab in PD-L1 positive metastatic anaplastic thyroid carcinoma: a case report

European journal of hospital pharmacy. Science and practice, 2021-03, Vol.28 (Suppl 1), p.A134-A134

2021

Link zum Volltext

Verfügbarkeit prüfen

A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events

Digestive and liver disease, 2024-02, Vol.56, p.S84

2024

Link zum Volltext

Verfügbarkeit prüfen

4CPS-152 Persistent cytopenia after CAR-T cells: treatment with eltrombopag: a case report

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A196-A197

2023

Link zum Volltext

Verfügbarkeit prüfen

3PC-020 Clobetasol petrolatum ointment 0.015% for the treatment of cutaneous graft-versus-host disease in paediatric patients: a case report

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A176-A176

2023

Link zum Volltext

Verfügbarkeit prüfen

4CPS-143 Core binding factor acute myeloid leukaemia following immune checkpoint inhibition for solid tumours: two case reports and literature state of the art

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A196-A196

2023

Link zum Volltext

Verfügbarkeit prüfen

4CPS-101 Trifluridine–tipiracil for metastatic colorectal cancer: real world data experience

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A94-A95

2020

Link zum Volltext

Verfügbarkeit prüfen

4CPS-003 Liraglutide in chronic intestinal failure: overview and case report

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A48-A49

2020

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of irinotecan in advanced colorectal cancer

Annals of oncology, 2000-07, Vol.11 (7), p.899-900

2000

Link zum Volltext

Verfügbarkeit prüfen

5PSQ-014 Novel oral anticoagulants vs vitamin K antagonists: a cost analysis

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A208-A208

2019

Link zum Volltext

Verfügbarkeit prüfen

4CPS-010 Safety and efficacy of low molecular weight heparins in patients with portal vein thrombosis

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A52-A52

2020

Link zum Volltext

Verfügbarkeit prüfen

4CPS-215 Access to ‘fondo AIFA 5%’ as an instrument supporting the sustainability in a shared clinical management of rare and difficult-to-treat diseases

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A169-A170

2019

Link zum Volltext

Verfügbarkeit prüfen

4CPS-148 Analysis of spontaneous reporting of adverse drug reactions in an italian population: alemtuzumab in the treatment of multiple sclerosis

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A111-A111

2018

Link zum Volltext

Verfügbarkeit prüfen

4CPS-031 Cost-minimisation analysis: tolvaptan versus urea and sodium chloride to treat syndrome of inappropriate antidiuretic hormone secretion

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A55-A55

2018

Link zum Volltext

Verfügbarkeit prüfen

Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol

Anti-cancer drugs, 2000-10, Vol.11 (9), p.701-706

2000

Link zum Volltext

Verfügbarkeit prüfen

DI-068 Gender difference in adverse drug reactions: analysis in italian population

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A143-A144

2017

Link zum Volltext

Verfügbarkeit prüfen

Survival Meta-Analysis of Individual Patient Data and Survival Meta-Analysis of Published (Aggregate) Data: Is There an Intermediate Approach between these Two Opposite Options?

Clinical drug investigation, 2000-11, Vol.20 (5), p.309-316

2000

Link zum Volltext

Verfügbarkeit prüfen

CP-105 Clinical trials in haematology

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A46-A46

2017

Link zum Volltext

Verfügbarkeit prüfen

CP-100 Pegylated interferon ALFA 2-A in myeloproliferative neoplasms

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A44-A44

2017

Link zum Volltext

Verfügbarkeit prüfen

CP-134 Analysys of therapeutic response and tolerability in patients treated with crizotinib in ALK positive NSCLC

European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A59-A59

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

P07 BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD) IN REAL‐LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL

S300: HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE REAL‐LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD)

Efficacy of nivolumab monotherapy in cirrhotic patients with advanced hepatocellular carcinoma: a single-center retrospective study

Single centre experience with Nivolumab as monotherapy in chirrotic patients with advanced HCC

Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: a report of two international experiences

5PSQ-175 Cytotoxic T lymphocyte antigen 4 mutations on T reg and abatacept: a paediatric case report

5PSQ-158 Off-label use of pembrolizumab in PD-L1 positive metastatic anaplastic thyroid carcinoma: a case report

A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events

4CPS-152 Persistent cytopenia after CAR-T cells: treatment with eltrombopag: a case report

3PC-020 Clobetasol petrolatum ointment 0.015% for the treatment of cutaneous graft-versus-host disease in paediatric patients: a case report

4CPS-143 Core binding factor acute myeloid leukaemia following immune checkpoint inhibition for solid tumours: two case reports and literature state of the art

4CPS-101 Trifluridine–tipiracil for metastatic colorectal cancer: real world data experience

4CPS-003 Liraglutide in chronic intestinal failure: overview and case report

Cost-effectiveness of irinotecan in advanced colorectal cancer

5PSQ-014 Novel oral anticoagulants vs vitamin K antagonists: a cost analysis

4CPS-010 Safety and efficacy of low molecular weight heparins in patients with portal vein thrombosis

4CPS-215 Access to ‘fondo AIFA 5%’ as an instrument supporting the sustainability in a shared clinical management of rare and difficult-to-treat diseases

4CPS-148 Analysis of spontaneous reporting of adverse drug reactions in an italian population: alemtuzumab in the treatment of multiple sclerosis

4CPS-031 Cost-minimisation analysis: tolvaptan versus urea and sodium chloride to treat syndrome of inappropriate antidiuretic hormone secretion

Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol

DI-068 Gender difference in adverse drug reactions: analysis in italian population

Survival Meta-Analysis of Individual Patient Data and Survival Meta-Analysis of Published (Aggregate) Data: Is There an Intermediate Approach between these Two Opposite Options?

CP-105 Clinical trials in haematology

CP-100 Pegylated interferon ALFA 2-A in myeloproliferative neoplasms

CP-134 Analysys of therapeutic response and tolerability in patients treated with crizotinib in ALK positive NSCLC

Suchergebnisse filtern